Breast Cancer Research | Volume 11 Issue 3

Submit a manuscript Register Follow us on

Explore journal

Articles

	Volume 11 Issue 3
	Comment
	Editorial Links between transforming growth factor-β and canonical Wnt signaling yield new insights into breast cancer susceptibility, suppression and tumor heterogeneity Angela Incassati, Alicia Pinderhughes, Rachel Eelkema, Pamela Cowin Breast Cancer Research 2009, 11:103 (20 May 2009) Abstract \| Full text \| PDF \| PubMed
	Editorial Challenges in studying the etiology of breast cancer subtypes Melissa A Troester, Theresa Swift-Scanlan Breast Cancer Research 2009, 11:104 (29 June 2009) Abstract \| Full text \| PDF \| PubMed
	Viewpoint Anti-VEGF therapy as adjuvant therapy: clouds on the horizon? Bryan P Schneider, George W Sledge Breast Cancer Research 2009, 11:303 (18 May 2009) Abstract \| Full text \| PDF \| PubMed
	Review
	Review Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Joan S Lewis-Wambi, V Craig Jordan Breast Cancer Research 2009, 11:206 (29 May 2009) Abstract \| Full text \| PDF \| PubMed
	Research
	Research article QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model Jessica Kalra, Corinna Warburton, Karen Fang, Lincoln Edwards, Tim Daynard, Dawn Waterhouse, Wieslawa Dragowska, Brent W Sutherland, Shoukat Dedhar, Karen Gelmon, Marcel Bally Breast Cancer Research 2009, 11:R25 (1 May 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Docetaxel combined with QLT0267, an integrin-linked kinase inhibitor, suppresses the Protein Kinase B signalling pathway and disrupts the normal architecture of breast cancer cells, potentially enhancing therapeutic activity.
	Research article Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression Cecilia Williams, Luisa Helguero, Karin Edvardsson, Lars-Arne Haldosén, Jan-Åke Gustafsson Breast Cancer Research 2009, 11:R26 (8 May 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Research article MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer Aoife J Lowery, Nicola Miller, Amanda Devaney, Roisin E McNeill, Pamela A Davoren, Christophe Lemetre, Vladimir Benes, Sabine Schmidt, Jonathon Blake, Graham Ball, Michael J Kerin Breast Cancer Research 2009, 11:R27 (11 May 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Research article Immunohistochemical characterization of subtypes of male breast carcinoma Yimin Ge, Nour Sneige, Mahmoud A Eltorky, Zhiqin Wang, E Lin, Yun Gong, Ming Guo Breast Cancer Research 2009, 11:R28 (14 May 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Luminal A and B subtypes are the main subtypes in male breast cancer, but have different immunophenotypical features compared to their female counterparts.
	Research article PI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture Gray W Pearson, Tony Hunter Breast Cancer Research 2009, 11:R29 (20 May 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary ERK1/2 and PI-3K activation induce cell behaviours that could contribute to invasive and recurrent growth of ductal carcinoma in situ, and these signalling pathways combined warrant further investigation in patients.
	Research article A constant risk for familial breast cancer? A population-based family study Kamila Czene, Marie Reilly, Per Hall, Mikael Hartman Breast Cancer Research 2009, 11:R30 (20 May 2009) Abstract \| Full text \| PDF \| PubMed
	Research article Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors Marilyn L Kwan, Lawrence H Kushi, Erin Weltzien, Benjamin Maring, Susan E Kutner, Regan S Fulton, Marion M Lee, Christine B Ambrosone, Bette J Caan Breast Cancer Research 2009, 11:R31 (22 May 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Research article WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth Yutaka Matsuda, Thomas Schlange, Edward J Oakeley, Anne Boulay, Nancy E Hynes Breast Cancer Research 2009, 11:R32 (27 May 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Research article The spatial distribution of radiodense breast tissue: a longitudinal study Snehal M Pinto Pereira, Valerie A McCormack, Sue M Moss, Isabel dos Santos Silva Breast Cancer Research 2009, 11:R33 (3 June 2009) Abstract \| Full text \| PDF \| PubMed
	Research article Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer Frank Wiesmann, Jürgen Veeck, Oliver Galm, Arndt Hartmann, Manel Esteller, Ruth Knüchel, Edgar Dahl Breast Cancer Research 2009, 11:R34 (15 June 2009) Abstract \| Full text \| PDF \| PubMed
	Research article Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy Christos Markopoulos, Urania Dafni, John Misitzis, Vasilios Zobolas, Evagelos Tzoracoleftherakis, Dimitrios Koukouras, Grigorios Xepapadakis, John Papadiamantis, Basileios Venizelos, Zoh Antonopoulou, Helen Gogas Breast Cancer Research 2009, 11:R35 (16 June 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Adjuvant therapy with the aromatase inhibitor exemestane does not detrimentally affect lipid profiles in postmenopausal women with breast cancer, despite concerns over the potential impact of these agents on cardiovascular health.
	Research article Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer Ruben Rene Gonzalez, Amber Watters, Yanbo Xu, Udai P Singh, David R Mann, Bo R Rueda, Manuel L Penichet Breast Cancer Research 2009, 11:R36 (16 June 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| 1 comment \| Editor’s summary Leptin-signaling inhibition has been shown to reduce tumour growth in a mouse model of breast cancer, supporting its potential use as a novel treatment for estrogen positive and negative breast cancer.
	Research article HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005 Katri Köninki, Minna Tanner, Anssi Auvinen, Jorma Isola Breast Cancer Research 2009, 11:R37 (18 June 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Despite a significant decrease in the proportion of HER-2 positive breast cancer in Finland between 1982 and 2005, its incidence at the population level was unchanged due to an increase in breast cancer cases.
	Research article Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women Valerie A McCormack, Mitch Dowsett, Elizabeth Folkerd, Nichola Johnson, Claire Palles, Ben Coupland, Jeff M Holly, Sarah J Vinnicombe, Nicholas M Perry, Isabel dos Santos Silva Breast Cancer Research 2009, 11:R38 (22 June 2009) Abstract \| Full text \| PDF \| PubMed
	Research article Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer Catherine Alix-Panabières, Jean-Pierre Vendrell, Monique Slijper, Olivier Pellé, Eric Barbotte, Grégoire Mercier, William Jacot, Michel Fabbro, Klaus Pantel Breast Cancer Research 2009, 11:R39 (23 June 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Research article Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours André Albergaria, Joana Paredes, Bárbara Sousa, Fernanda Milanezi, Vítor Carneiro, Joana Bastos, Sandra Costa, Daniella Vieira, Nair Lopes, Eric W Lam, Nuno Lunet, Fernando Schmitt Breast Cancer Research 2009, 11:R40 (23 June 2009) Abstract \| Full text \| PDF \| PubMed
	Research article Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer Fiona M Foster, Thomas W Owens, Jolanta Tanianis-Hughes, Robert B Clarke, Keith Brennan, Nigel J Bundred, Charles H Streuli Breast Cancer Research 2009, 11:R41 (29 June 2009) Abstract \| Full text \| PDF \| PubMed
	Research article The role of YY1 in reduced HP1α gene expression in invasive human breast cancer cells Jason G Lieberthal, Marissa Kaminsky, Christopher N Parkhurst, Naoko Tanese Breast Cancer Research 2009, 11:R42 (30 June 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Correspondence
	Letter Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer Ingrid Ljuslinder, Irina Golovleva, Roger Henriksson, Kjell Grankvist, Beatrice Malmer, Håkan Hedman Breast Cancer Research 2009, 11:403 (12 May 2009) Abstract \| Full text \| PDF \| PubMed

	Volume 11 Issue 3
	Comment
	Editorial Links between transforming growth factor-β and canonical Wnt signaling yield new insights into breast cancer susceptibility, suppression and tumor heterogeneity Angela Incassati, Alicia Pinderhughes, Rachel Eelkema, Pamela Cowin Breast Cancer Research 2009, 11:103 (20 May 2009) Abstract \| Full text \| PDF \| PubMed
	Editorial Challenges in studying the etiology of breast cancer subtypes Melissa A Troester, Theresa Swift-Scanlan Breast Cancer Research 2009, 11:104 (29 June 2009) Abstract \| Full text \| PDF \| PubMed
	Viewpoint Anti-VEGF therapy as adjuvant therapy: clouds on the horizon? Bryan P Schneider, George W Sledge Breast Cancer Research 2009, 11:303 (18 May 2009) Abstract \| Full text \| PDF \| PubMed
	Review
	Review Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Joan S Lewis-Wambi, V Craig Jordan Breast Cancer Research 2009, 11:206 (29 May 2009) Abstract \| Full text \| PDF \| PubMed
	Research
	Research article QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model Jessica Kalra, Corinna Warburton, Karen Fang, Lincoln Edwards, Tim Daynard, Dawn Waterhouse, Wieslawa Dragowska, Brent W Sutherland, Shoukat Dedhar, Karen Gelmon, Marcel Bally Breast Cancer Research 2009, 11:R25 (1 May 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Docetaxel combined with QLT0267, an integrin-linked kinase inhibitor, suppresses the Protein Kinase B signalling pathway and disrupts the normal architecture of breast cancer cells, potentially enhancing therapeutic activity.
	Research article Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression Cecilia Williams, Luisa Helguero, Karin Edvardsson, Lars-Arne Haldosén, Jan-Åke Gustafsson Breast Cancer Research 2009, 11:R26 (8 May 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Research article MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer Aoife J Lowery, Nicola Miller, Amanda Devaney, Roisin E McNeill, Pamela A Davoren, Christophe Lemetre, Vladimir Benes, Sabine Schmidt, Jonathon Blake, Graham Ball, Michael J Kerin Breast Cancer Research 2009, 11:R27 (11 May 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Research article Immunohistochemical characterization of subtypes of male breast carcinoma Yimin Ge, Nour Sneige, Mahmoud A Eltorky, Zhiqin Wang, E Lin, Yun Gong, Ming Guo Breast Cancer Research 2009, 11:R28 (14 May 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Luminal A and B subtypes are the main subtypes in male breast cancer, but have different immunophenotypical features compared to their female counterparts.
	Research article PI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture Gray W Pearson, Tony Hunter Breast Cancer Research 2009, 11:R29 (20 May 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary ERK1/2 and PI-3K activation induce cell behaviours that could contribute to invasive and recurrent growth of ductal carcinoma in situ, and these signalling pathways combined warrant further investigation in patients.
	Research article A constant risk for familial breast cancer? A population-based family study Kamila Czene, Marie Reilly, Per Hall, Mikael Hartman Breast Cancer Research 2009, 11:R30 (20 May 2009) Abstract \| Full text \| PDF \| PubMed
	Research article Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors Marilyn L Kwan, Lawrence H Kushi, Erin Weltzien, Benjamin Maring, Susan E Kutner, Regan S Fulton, Marion M Lee, Christine B Ambrosone, Bette J Caan Breast Cancer Research 2009, 11:R31 (22 May 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Research article WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth Yutaka Matsuda, Thomas Schlange, Edward J Oakeley, Anne Boulay, Nancy E Hynes Breast Cancer Research 2009, 11:R32 (27 May 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Research article The spatial distribution of radiodense breast tissue: a longitudinal study Snehal M Pinto Pereira, Valerie A McCormack, Sue M Moss, Isabel dos Santos Silva Breast Cancer Research 2009, 11:R33 (3 June 2009) Abstract \| Full text \| PDF \| PubMed
	Research article Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer Frank Wiesmann, Jürgen Veeck, Oliver Galm, Arndt Hartmann, Manel Esteller, Ruth Knüchel, Edgar Dahl Breast Cancer Research 2009, 11:R34 (15 June 2009) Abstract \| Full text \| PDF \| PubMed
	Research article Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy Christos Markopoulos, Urania Dafni, John Misitzis, Vasilios Zobolas, Evagelos Tzoracoleftherakis, Dimitrios Koukouras, Grigorios Xepapadakis, John Papadiamantis, Basileios Venizelos, Zoh Antonopoulou, Helen Gogas Breast Cancer Research 2009, 11:R35 (16 June 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Adjuvant therapy with the aromatase inhibitor exemestane does not detrimentally affect lipid profiles in postmenopausal women with breast cancer, despite concerns over the potential impact of these agents on cardiovascular health.
	Research article Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer Ruben Rene Gonzalez, Amber Watters, Yanbo Xu, Udai P Singh, David R Mann, Bo R Rueda, Manuel L Penichet Breast Cancer Research 2009, 11:R36 (16 June 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| 1 comment \| Editor’s summary Leptin-signaling inhibition has been shown to reduce tumour growth in a mouse model of breast cancer, supporting its potential use as a novel treatment for estrogen positive and negative breast cancer.
	Research article HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005 Katri Köninki, Minna Tanner, Anssi Auvinen, Jorma Isola Breast Cancer Research 2009, 11:R37 (18 June 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Despite a significant decrease in the proportion of HER-2 positive breast cancer in Finland between 1982 and 2005, its incidence at the population level was unchanged due to an increase in breast cancer cases.
	Research article Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women Valerie A McCormack, Mitch Dowsett, Elizabeth Folkerd, Nichola Johnson, Claire Palles, Ben Coupland, Jeff M Holly, Sarah J Vinnicombe, Nicholas M Perry, Isabel dos Santos Silva Breast Cancer Research 2009, 11:R38 (22 June 2009) Abstract \| Full text \| PDF \| PubMed
	Research article Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer Catherine Alix-Panabières, Jean-Pierre Vendrell, Monique Slijper, Olivier Pellé, Eric Barbotte, Grégoire Mercier, William Jacot, Michel Fabbro, Klaus Pantel Breast Cancer Research 2009, 11:R39 (23 June 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Research article Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours André Albergaria, Joana Paredes, Bárbara Sousa, Fernanda Milanezi, Vítor Carneiro, Joana Bastos, Sandra Costa, Daniella Vieira, Nair Lopes, Eric W Lam, Nuno Lunet, Fernando Schmitt Breast Cancer Research 2009, 11:R40 (23 June 2009) Abstract \| Full text \| PDF \| PubMed
	Research article Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer Fiona M Foster, Thomas W Owens, Jolanta Tanianis-Hughes, Robert B Clarke, Keith Brennan, Nigel J Bundred, Charles H Streuli Breast Cancer Research 2009, 11:R41 (29 June 2009) Abstract \| Full text \| PDF \| PubMed
	Research article The role of YY1 in reduced HP1α gene expression in invasive human breast cancer cells Jason G Lieberthal, Marissa Kaminsky, Christopher N Parkhurst, Naoko Tanese Breast Cancer Research 2009, 11:R42 (30 June 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Correspondence
	Letter Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer Ingrid Ljuslinder, Irina Golovleva, Roger Henriksson, Kjell Grankvist, Beatrice Malmer, Håkan Hedman Breast Cancer Research 2009, 11:403 (12 May 2009) Abstract \| Full text \| PDF \| PubMed

Explore journal

Articles

Volume 11 Issue 3

Comment

Review

Research

Correspondence